Response of Epstein-Barr virus-associated K1-1+ anaplastic large cell lymphoma to 13-cis retinoic acid and interferon alpha

Journal of the Formosan Medical Association

Volumn 97, Issue 6, 1998, Pages 420-424

  Chen, Gong Shen ^a   Chang, Yi Fang ^a   Chang, Ming Chi ^a   Tsan, Kun Wu ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

13 cis retinoic acid; Anaplastic large cell lymphoma; Epstein Barr virus; Hemophagocytic syndrome; Interferon alpha; Peripheral T cell lymphoma

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN G; ISOTRETINOIN; METHOTREXATE; VINCRISTINE;

ADULT; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HYPERTRIGLYCERIDEMIA; INTRAVENOUS DRUG ADMINISTRATION; LARGE CELL LYMPHOMA; MALE; MYALGIA; SALVAGE THERAPY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON-ALPHA; ISOTRETINOIN; LYMPHOMA, LARGE-CELL, KI-1; MALE; TUMOR VIRUS INFECTIONS;

EID: 0031823982     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Warrel RP, Coonley CJ, Kempin SJ, et al.: Isotretinoin in cutaneous T-cell lymphoma. Lancet 1983,2:629-35.
2. Peck R, Bollag W: Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer 1991;27:53-7.
3. Bollag W, Peck R, Frey JR: Inhibition of proliferation by retinoids, cytokines and their combination in four human transformed epithelial cell lines. Cancer Lett 1992; 62:167-72.
4. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al.: 13-cis-RA plus Interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992;84:241-5.
5. Avidano MR, Singleton GT: Adjuvant drug strategies in the treatment of recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1994;112:197-202.
6. Lippman SM, Benner SE, Hong WK: Chemoprevention strategies in lung carcinogensis. Chest 1993;103: 15S-19S.
7. Chou WC, Su IJ, Tien HF et al.: Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: special emphasis on the tumor response to 13-cis-retinoic acid. Cancer 1996; 78:1805-12.
8. Cheng AL, Su IJ, Chen CC, et al.: Use of retinoic acid in the treatment of PTCL: a pilot study. J Clin Oncol 1994;12:1185-92.
9. Nagy L, Thomazy VA, Chandraratna RA, et al.: Retinoid-regulated expression of BCL-2 and apoptosis of human HL-60 cells Leuk Res 1996;16:17-24.
10. Su IJ, Chen RL, Lin DT, et al.: EBV infects T lymphoma in childhood EBV-associated-hemophagocytic syndrome in Taiwan. Am J Pathol 1994;144,1219-25.
11. Gaffey MJ, Frierson HF, Medeiros LJ, et al.: The relationship of EBV to infection-related (sporadic) and familial hemophgocytic syndrome and secondary (lymphoma-related) hemophgocytosis: an in situ hybridization study. Hum Pathol 1993;24:657-67.
12. Wong KF, Chang JKC, Lo ESF, et al.: A study of the possible etiologic association of EBV with reactive hemophgocytic syndrome in Hong Kong Chinese. Hum Pathol 1996;27:239-42.
13. Goulder P, Seward D, Hatton C, et al.: Intravenous immunoglobulin in virus-associated hemophagocytic syndrome. Arch Dis Child 1990;65:1275-7.
14. Ambruso DR, Hays T, Zwartjes WJ, et al.: Successful treatment of lymphohistiocytosis with epipodophyllotoxin VP 16-213. Cancel 1980;45:2516-20.
15. Lopategui JR, Gaffey MJ, Chan KC, et al.: Infrequent association of EBV with CD30 positive ALCL from American and Asian patients. Am J Surg Pathol 1995; 19:42-9.
16. Yao M, Cheng AL, Su IJ, et al.: Clinicopathological spectrum of hemophagocytic syndrome in EBV-associated peripheral T-cell lymphoma. Br J Haematol 1994;87: 35-43.
17. Simrell CR, Margolick JB, Crabtree GR, et al.: Lymphokine-induced phagocytosis in angiocentric immunoproliferative lesions (AIL) and malignant lymphoma arising in AIL. Blood 1985;65:1469-76.
18. Cheng AL, Su IJ, Chen YC, et al.: Characteristic clinicopathological features of EBV-associated PTCL. Cancer 1993;72:909-16.
19. Janssen HLA, Brouwer JT, Neven F, et al.: Fatal hepatic decompensation associated with interferon alfa. BMJ 1993;306:107-8.
20. Newcom SR, Kadin M, Ansai A: Production of transforming growth factor-beta activity by Ki-1 positive lymphoma growth. Am J Pathol 1988;131:569-77.
21. Newcom SR, Tagra KK, Kadin ME: Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells: further evidence for negative autocrine regulation by transforming growth factor beta. Am J Pathol 1992;140:709-18.
22. Kadin M, Cavaille-Coll M, Morton C: Tumor progression in Ki-1 cutaneous T-cell lymphomas is related to escape from inhibition by transforming growth factor-beta [Abstract]. Blood 1990;76:354a.
23. Josephia RF, Young CW, Jr Warrell RP: Clinical pharmacology of all-trans retinoid acid. Leukemia 1994;8:1807-12.
24. Waladkhani AR, Clemens MR: Differences in the pharmacokinetics of 13-cis retinoic acid in cancer patients. Int J Cancel 1997;70:494-5.
25. 2+ elevation and cyclosporin A syngeristically induce TGF-beta 1-mediated apoptosis in lymphocytes. J Immunol 1997; 158:2527-34.